Volume 22, Issue 2, 15 February 2015, Pages 290–296
Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial
Abstract
Aim:
Diabetes is a serious metabolic disorder and oxidative stress and
inflammation contribute to its pathogenesis and complications. Since Silybum marianum (L.) Gaertn.
(silymarin) extract is an antioxidant with anti-inflammatory
properties, this randomized clinical trial was conducted to evaluate the
effects of silymarin supplementation on oxidative stress indices and
hs-CRP in type 2 diabetes mellitus patients.
Methods:
For the present paralleled, randomized, triple-blinded,
placebo-controlled clinical trial, 40 type 2 diabetes patients aged
25–50 yr old and on stable medication were recruited from the Iranian
Diabetes Society and endocrinology clinics in East Azarbayjan (Tabriz,
Iran) and randomly assigned into two groups. Patients in the silymarin
treatment group received 140 mg, thrice daily of dried extracts of Silybum marianum (n = 20) and those in the placebo group (n
= 20) received identical placebos for 45 days. Data pertaining to
height, weight, waist circumference and BMI, as well as food
consumption, were collected at base line and at the conclusion of the
study. Fasting blood samples were obtained and antioxidant indices and
hs-CRP were assessed at baseline, as well as at the end of the trial.
Results:
All 40 patients completed the study and did not report any adverse
effects or symptoms with the silymarin supplementation. Silymarin
supplementation significantly increased superoxide dismutase (SOD),
glutathione peroxidase (GPX) activity and total antioxidant capacity
(TAC) compared to patients taking the placebo, by 12.85%, 30.32% and
8.43%, respectively (p < 0.05). There was a significant reduction in hs-CRP levels by 26.83% (p
< 0.05) in the silymarin group compared to the placebo group.
Malondialdehyde (MDA) concentration significantly decreased by 12.01% (p < 0.05) in the silymarin group compared to the baseline.
Conclusions: Silymarin supplementation improves some antioxidant indices (SOD, GPX and TAC) and decrease hs-CRP levels in T2DM patients.
Graphical abstract
Keywords
- Diabetes mellitus;
- Silymarin;
- hs-CRP;
- Malondialdehyde;
- Antioxidants
- Corresponding author. Tel.:
+984113357580; fax: +984113340634.
Copyright © 2015 Published by Elsevier GmbH
